The HOPE Study – Approaching Dementia Treatment Differently

Lori La Bey talks with Ralph Kern, M.D., who is Chief Medical Officer at Cognito Therapeutics, a company developing a disease-modifying at-home therapy for Alzheimer’s Disease. He has over 17 years of biotech experience including senior medical roles at Genzyme, Novartis, and Biogen.

Learn:

1. About brain changes
2. Lifestyle factors and genetics
3. If early diagnosis helps
4. At home treatment
5. Light, sound, sensory stimulation
6. Biophysical changes
7. Decreased clinic visits
8. HOPE Study 

 

Watch the Video Interview Below

https://youtu.be/dRY6PWEvZds

 

Listen and Subscribe to Alzheimer’s Speaks on Apple Podcast

https://podcasts.apple.com/us/podcast/alzheimers-speaks/id986940432

 

Listen and Subscribe to Alzheimer’s Speaks on Spotify

https://open.spotify.com/show/255okRnEgfCUqXq1NWcrT3

 

Contact Cognito Therapeutics Inc. 

LinkedIn for Cognito Therapeutics - https://www.linkedin.com/company/cognito-therapeutics-inc./

Twitter for Cognito Therapeutics - @cognitotx

LinkedIn for Ralph Kern - https://www.linkedin.com/in/ralphkernsvpbiotech/

Cognito website - www.cognitotx.com

HOPE study website - www.hopestudyforad.com

 

Contact Lori La Bey with questions or branding needs at https://www.alzheimersspeaks.com/

Alzheimer's Speaks Radio - Shifting dementia care from crisis to comfort around the world one episode at a time by raising all voices and delivering sound news, not just sound bites since 2011.

Alzheimer's Speaks is part of the Senior Resource Podcast Network

Support this Show: https://alzheimersspeaks.com/donate-now/

See omnystudio.com/listener for privacy information.